Markus Maeurer is an expert in Infectiology at Johannes Gutenberg University Mainz (Germany). Markus Maeurer has authored 353 publications, the most recent in 2026, and is an investigator in 1 clinical trial. SLR score: 1,127 (community average: 125). How the SLR is computed.

LeadR Profile

1 127 ScienceLeadR Reputation 1127
Network Map

Infectiology

Subspecialties: Oncology - Immunology - Pulmonology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1992 - 2026

Source: PubMed

Johannes Gutenberg University Mainz

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 353

Citations

Citations: 17 489 1st author: 26 Last author: 145 Unique author: 4


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
S1P in Tumor Microenvironment and Modulation of Anti-Tumor-Directed T-Cell Responses.
PMID 42193918 — cells, neoplasms, therapeutics, t-lymphocytes, tumor microenvironment
Cells20260
Cardiolipin Induces CXCL9/CXCL10 Expression in Tumor-Infiltrating Lymphocytes.
PMID 42121899 — cytokines, cells, pancreatic neoplasms, mitochondrial proteins, lymphocytes, lymphocytes, tumor-infiltrating, cardiolipins, neoplasms, mitochondria, inflammasomes, gastrointestinal neoplasms, tissues, mutation, membranes
Cells20260
Tumor-Infiltrating Natural Killer Cell Characterization in Pancreatic Ductal Adenocarcinoma.
PMID 42121898 — cells, killer cells, natural, neoplasms, adenocarcinoma, phenotype, therapeutics
Cells20260
TCRcloud: a global visualization tool for T-cell and B-cell receptor transcripts.
PMID 41652507 — cells, pancreatic neoplasms, blood, biomedical research, amino acids, neoplasms, immunity, therapeutics, software, tissues, t-lymphocytes, b-lymphocytes
J Transl Med20260
Protecting the future of vaccine development amidst US funding withdrawal for mRNA vaccine research.
PMID 40912261 — vaccines, rna, messenger, research, vaccine development
Lancet Microbe20250

Clinical Studies 1

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 2 1

By status:

Completed 1

By type:

Interventional 1

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 1
multicentric5to9 0
multicentricup10 0

Main Topics

LeadR Networks

Main global connection map